Pedigree analysis of a subject with abnormally slow renal elimination of 6-hydroxychlorzoxazone

Pharmacology

Volumn 56, Issue 5, 1998, Pages 262-266

  Vesell, Elliot S ^a   Korsunsky, Zhanna ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Chlorzoxazone; CYP 2E1; In vivo probe; Interindividual variations

Indexed keywords

CHLORZOXAZONE; DRUG METABOLITE;

ADULT; ARTICLE; DRUG ELIMINATION; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PEDIGREE ANALYSIS; PRIORITY JOURNAL; TABLET; URINARY EXCRETION;

ADULT; BIOTRANSFORMATION; CHILD; CHLORZOXAZONE; CYTOCHROME P-450 CYP2E1; FEMALE; HALF-LIFE; HUMANS; MALE; PEDIGREE;

EID: 0031917073     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000028207     Document Type: Article

References (7)

1. Vesell ES, DeAngelo Seaton T, A-Rahim YI: Studies on interindividual variations of CYP 2E1 using chlorzoxazone as an in vivo probe. Pharmacogenetics 1995;5:53-57.
2. Desiraju RK, Renzi NL Jr, Nayak RK, Ng K-T: Pharmacokinetics of chlorzoxazone in humans. J Pharm Sci 1983;72:991-994.
3. Cummings AJ, Martin BK, Park GS: Kinetic considerations relating to the accrual and elimination of drug metabolites. Br J Pharmacol Chemother 1967;29:136-149.
4. Martin BK: Drug urinary excretion data: Some aspects concerning the interpretation. Br J Pharmacol Chemother 1967;29:181-193.
5. Kyerematen GA, Vesell ES: Metabolism of nicotine. Drug Metab Rev 1991;23:3-41.
6. Carrière V, Berthou F, Baird S, Belloc C, Beaune P, DeWaziers I: Human cytochrome P450 2E1 (CYP2E1): from genotype to phenotype. Pharmacogenetics 1996;6: 203-211.
7. Kim RB, O'Shea D, Wilkinson GR: Relationship in healthy subjects between CYP2E1 genetic polymorphisms and the 6-hydroxylation of chlorzoxazone: A putative measure of CYP2E1 activity. Pharmacogenetics 1994;4:162-165.